A Rare but Morbid Occurrence: Development of Glioblastoma Multiforme During Tumor Necrosis Factor Inhibitor Therapy

The use of biologic therapies continues to become more prevalent in the treatment of inflammatory bowel disease, particularly for more severe disease. Although generally safe and effective, specific biologic classes such as tumor necrosis factor inhibitor (anti-TNF) medications are known to increase...

Full description

Saved in:
Bibliographic Details
Published in:Curēus (Palo Alto, CA) CA), 2022-05, Vol.14 (5)
Main Authors: Kraemer, Laura S, Humes, Ross J, Syed, Azfar S, Tritsch, Adam M
Format: Article
Language:English
Subjects:
Brain cancer
Cancer therapies
Case reports
Crohn's disease
Gastroenterology
Inflammatory bowel disease
Irritable bowel syndrome
Medical prognosis
Melanoma
Monoclonal antibodies
Necrosis
Oncology
Patients
Radiation
Remission (Medicine)
Skin cancer
Steroids
Therapeutics
Tumor necrosis factor-TNF
Tumorigenesis
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The use of biologic therapies continues to become more prevalent in the treatment of inflammatory bowel disease, particularly for more severe disease. Although generally safe and effective, specific biologic classes such as tumor necrosis factor inhibitor (anti-TNF) medications are known to increase the risk of certain cancers. Glioblastoma multiforme (GBM) is an aggressive brain tumor which tends to arise sporadically but may be associated with anti-TNF therapies. Here, we present a case of a 69-year-old male with Crohn’s disease who developed GBM while on adalimumab therapy. This case report highlights the potential rare association between GBM and anti-TNF therapy and further discusses the difficulty of managing active Crohn’s disease with concomitant GBM, specifically the difficulty encountered in managing a disease flare.
ISSN:2168-8184
2168-8184
DOI:10.7759/cureus.25027